What does Beam Therapeutics do?
Beam Therapeutics Inc. is a Nasdaq-listed clinical-stage biotechnology company developing precision genetic medicines. Its core technology is base editing, designed to change a targeted DNA letter without creating a programmed double-stranded break. Beam’s base-editing science overview describes a guided CRISPR protein paired with an editing enzyme that converts one base into another.
Why is base editing different from traditional nuclease editing?
| Research dimension | Beam position | Why it matters |
|---|---|---|
| Core technology | Adenine and cytosine base editors | Targets single-base changes without a programmed double-stranded DNA break. |
| Delivery | Ex vivo electroporation and in vivo lipid nanoparticles | Allows different treatment designs for blood cells and liver-targeted diseases. |
| Operating model | Integrated editing, delivery, clinical development, and manufacturing capabilities | Reduces dependence on a single external technology layer, although suppliers and partners remain important. |
| Current commercial status | No approved products as of the first quarter of 2026 | The company is valued primarily on clinical, regulatory, financing, and future commercialization outcomes. |
How does Beam Therapeutics make money before product approval?
What did collaboration revenue represent in 2025 and early 2026?
Fiscal 2025 license and collaboration revenue was $139.7 million, versus $63.5 million in 2024, including $109.1 million recognized when the Pfizer research collaboration concluded. Q1 2026 revenue was $31.7 million versus $7.5 million a year earlier, mainly from a $25.0 million Lilly milestone. The first-quarter 2026 Form 10-Q confirms that milestone timing, not product volume, drove the increase.
Why do partnerships matter beyond near-term revenue?
Pfizer’s 2025 opt-in to a liver-targeted candidate validated the platform and transferred later development responsibility to a larger partner. Beam remains eligible for up to $350.0 million of development, regulatory, and commercial milestones, plus royalties, and may elect a 35% share of global development costs and profits after Phase 1/2. Such agreements broaden platform reach while preserving internal capital for priority assets.
Which programs matter most to Beam’s pipeline?
| Program | Disease | Approach | Status by June 2026 | Key next step |
|---|---|---|---|---|
| Risto-cel | Severe sickle cell disease | Ex vivo autologous stem-cell base editing | Phase 1/2 BEACON | Potential U.S. BLA submission as early as year-end 2026. |
| BEAM-302 | Alpha-1 antitrypsin deficiency | In vivo liver-targeted LNP | Phase 1/2; 60 mg selected | Start an approximately 50-patient pivotal cohort in the second half of 2026. |
| BEAM-301 | Glycogen storage disease Ia | In vivo liver-targeted LNP | Phase 1/2 | Report initial clinical data in 2026. |
| BEAM-304 | Phenylketonuria | Mutation-specific in vivo liver-targeted LNP | IND cleared June 18, 2026 | Initiate Phase 1/2 work, initially in R408W patients. |
| ESCAPE / BEAM-103 | Sickle cell disease and beta-thalassemia | Edited-cell and anti-CD117 conditioning pair | Phase 1 healthy-volunteer work | Establish a non-genotoxic conditioning path. |
Why are risto-cel and BEAM-302 the lead value drivers?
Risto-cel is closest to a potential filing: Beam reported durable biological and clinical effects in 31 BEACON patients and targets a possible BLA submission as early as year-end 2026. BEAM-302 is the leading in vivo proof point. As of February 10, 2026, 29 patients had been treated; at 60 mg, mean steady-state total AAT reached 16.1 micromolar, corrected M-AAT represented 94% of circulating AAT, and mutant Z-AAT declined 84%. The March 2026 clinical update reported no serious adverse events or dose-limiting toxicities among single-dose patients through the cutoff.
How do BEAM-301 and BEAM-304 test platform breadth?
BEAM-301 targets the R83C mutation in GSDIa and measures fasting tolerance and cornstarch use. BEAM-304 extends the platform to genetically heterogeneous PKU. Its IND was cleared on June 18, 2026, initially covering two variants found in nearly half of U.S. PKU patients. The IND clearance announcement tests whether one delivery and manufacturing platform can support multiple mutation-specific editors.
What does Beam’s latest reporting period show?
What changed in the first quarter of 2026?
Q1 2026 revenue increased $24.3 million year over year because of the Lilly milestone. R&D rose $5.7 million to $104.5 million and G&A rose $6.5 million to $34.4 million. Operating loss narrowed to $107.2 million from $119.3 million, while net loss narrowed to $94.3 million, or $0.91 per share, from $108.3 million, or $1.23 per share.
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| License and collaboration revenue | $31.7M | $7.5M | Increase was milestone-driven, not product-sales growth. |
| R&D expense | $104.5M | $98.8M | Clinical, manufacturing, people, and platform spending remained the dominant cost. |
| G&A expense | $34.4M | $27.9M | Commercial readiness and legal activity increased the support-cost base. |
| Operating loss | $(107.2)M | $(119.3)M | Improved because collaboration revenue rose faster than operating expense. |
| Net loss | $(94.3)M | $(108.3)M | Interest income and other items partly offset operating losses. |
| Operating cash flow | $(128.5)M | $(103.9)M | Cash use worsened despite a smaller accounting loss because working-capital movements consumed cash. |
| Property and equipment purchases | $2.2M | $3.1M | Near-term cash burn is driven more by research operations than conventional capex. |
Which turning points shaped Beam’s current strategy?
-
2017Beam was founded around foundational base-editing intellectual property. This established the technology-first model that still underpins every internal and partnered program.
-
2020The initial public offering supplied capital for platform expansion, delivery work, manufacturing, and clinical development before product revenue existed.
-
2021Beam acquired Guide Therapeutics and entered major collaborations, including Pfizer, strengthening nonviral delivery capabilities and partner-funded reach.
-
2022The BEACON trial began evaluating the program now called risto-cel, moving Beam from platform promise into human clinical evidence.
-
2023A portfolio restructuring eliminated about 100 positions, roughly 20% of the workforce, and concentrated resources on near-term hematology and liver programs.
-
2025Clinical data strengthened the cases for risto-cel and BEAM-302, Pfizer opted into a liver-targeted candidate, and the Orbital acquisition generated $255.1M of closing cash consideration for Beam’s stake.
-
2026Beam selected the 60 mg BEAM-302 dose, advanced toward pivotal development, prepared risto-cel for a potential BLA, secured a strategic financing facility, and obtained IND clearance for BEAM-304.
What did the 2023 restructuring change?
What gives Beam a competitive advantage in base editing?
Where does the moat come from?
Beam’s potential moat combines intellectual property, editor engineering, delivery, clinical datasets, manufacturing capability, and specialized talent. Each treated patient adds knowledge about dose, biodistribution, safety, controls, and regulatory expectations. The advantage is therefore cumulative, but only if clinical outcomes remain reproducible.
Who are Beam’s main competitors?
| Competitive axis | Beam’s position | Pressure point |
|---|---|---|
| Editing precision | Designed for targeted base changes without programmed double-strand breaks | Off-target editing, bystander edits, and long-term safety still require clinical proof. |
| Delivery | Clinical experience in ex vivo cells and liver-targeted LNPs | Efficient delivery outside blood and liver remains a sector-wide challenge. |
| Pipeline maturity | Risto-cel may reach a BLA submission; BEAM-302 is moving toward pivotal development | Competitors may have approved products, larger commercial organizations, or alternative conditioning. |
| Platform scalability | BEAM-304 proposes multiple mutation-specific editors within one development framework | Regulatory acceptance of platform-based extrapolation is still evolving. |
How strong are Beam’s finances and capital runway?
What does the annual financial pattern reveal?
Annual results show why conventional revenue multiples can mislead. Collaboration revenue was $377.7 million in 2023, $63.5 million in 2024, and $139.7 million in 2025. The 2025 net loss of $80.0 million included a $255.1 million Orbital-related gain; operating loss was $383.7 million and operating cash use was $345.1 million. The audited 2025 annual report supports emphasizing operating loss and cash burn.
How are research costs changing?
Does the balance sheet support the clinical plan?
At March 31, 2026, Beam held $288.3 million of cash and $923.4 million of marketable securities, with $100.2 million of long-term debt and $1.16 billion of equity. Management expects available liquidity plus an anticipated additional $100 million from Sixth Street to fund operations into mid-2029. The financing announcement describes $100 million funded at closing, up to $400 million of additional availability, and a seven-year term.
| Balance-sheet or cash metric | Period | Amount | Analytical meaning |
|---|---|---|---|
| Cash and equivalents | March 31, 2026 | $288.3M | Immediate liquidity. |
| Marketable securities | March 31, 2026 | $923.4M | Primary runway reserve, largely liquid fixed-income instruments. |
| Operating cash use | Q1 2026 | $(128.5)M | Quarterly burn was elevated by working-capital changes. |
| Long-term debt | March 31, 2026 | $100.2M | Adds non-equity capital but creates fixed obligations and potential milestone-linked economics. |
| Property and equipment, net | March 31, 2026 | $101.2M | Reflects laboratories, manufacturing-related infrastructure, and leasehold investment. |
| Projected runway | Company estimate, May 2026 | Into mid-2029 | Intended to cover risto-cel launch preparation, BEAM-302 pivotal work, and BEAM-304 proof of concept. |
Who owns Beam stock, and how is it governed?
What does the ownership structure signal?
Beam has one common share class with one vote per share and no founder-controlled dual-class structure. The 2026 proxy reported 100.6 million shares outstanding at December 31, 2025. Directors and executive officers as a group beneficially owned 3.9 million shares, or 3.8%, while CEO John Evans held 2.0%.
| Holder or group | Beneficial shares | Reported stake | Source period | Why it matters |
|---|---|---|---|---|
| FMR LLC and affiliates | 12,750,369 | 12.7% | Proxy table, December 31, 2025 | Large active institutional influence. |
| ARK Investment Management and affiliates | 12,467,189 | 12.4% | Proxy table, December 31, 2025 | Concentrated thematic ownership can amplify reactions to clinical news. |
| Farallon Capital Partners and affiliates | 10,141,856 | 10.1% | Proxy table, December 31, 2025 | Specialist capital may focus strongly on milestone execution. |
| BlackRock, Inc. | 7,499,930 | 7.5% | Proxy table, December 31, 2025 | Broad institutional participation supports liquidity and governance scrutiny. |
| State Street Corporation | 5,228,529 | 5.2% | Proxy table, December 31, 2025 | Passive ownership can shape voting outcomes. |
| Directors and executive officers, 11 persons | 3,942,471 | 3.8% | Proxy table, December 31, 2025 | Meaningful incentive alignment without absolute voting control. |
The 2026 proxy statement also notes an unusual disclosure transition for Vanguard: its reported 7.6% table position was based partly on earlier reporting and company records, while a March 2026 Schedule 13G amendment stated that Vanguard no longer aggregated beneficial ownership after an internal reorganization. This illustrates why ownership tables should be read with their stated dates and footnotes.
How do governance and incentives affect the strategy?
Without controlling founder votes, the board and institutional shareholders have meaningful influence over financing, incentives, portfolio choices, and commercialization spending. Stock-based compensation was $94.2 million in fiscal 2025 and $19.0 million in Q1 2026. At March 31, 2026, 12.7 million options were outstanding at a weighted-average exercise price of $34.66, making dilution a material monitoring item.
What opportunities and risks could change Beam’s story?
Which opportunities are most consequential?
Which filing-sourced risks deserve the most attention?
| Risk | Financial or strategic channel | What to monitor |
|---|---|---|
| Clinical safety or efficacy disappointment | Lower probability of approval, delay, program termination, or reduced partnering value | Serious adverse events, dose-limiting toxicities, durability, and patient-to-patient consistency. |
| Regulatory uncertainty | Longer trials, new endpoints, post-approval requirements, or rejection of accelerated pathways | FDA feedback on BEAM-302 biomarkers, risto-cel filing readiness, and platform-based development. |
| Manufacturing complexity | Higher cost, supply interruption, launch constraints, or comparability problems | Batch consistency, capacity, release testing, and treatment-center logistics. |
| Intellectual-property disputes | Legal cost, royalties, restricted freedom to operate, or loss of exclusivity | Patent proceedings involving base editors, CRISPR components, delivery, or licensed rights. |
| Financing and dilution | Equity issuance, debt obligations, or reduced strategic flexibility | Quarterly operating cash use, facility draws, stock compensation, and runway revisions. |
| Commercial adoption and reimbursement | Lower patient uptake or pricing than clinical value implies | Conditioning burden, center capacity, payer policies, durability evidence, and competing therapies. |
Why does Beam’s business model matter for valuation?
Which drivers belong in a DCF or scenario model?
A DCF based on current revenue is poorly suited to Beam because collaboration revenue is volatile and product sales have not begun. A program-based model should estimate each asset’s probability of success, launch timing, eligible population, penetration, net price, cost of goods, commercialization expense, royalties, milestones, and exclusivity period. Cash and debt then bridge program value to equity value.
Which KPIs should researchers monitor next?
What is the key takeaway from Beam Therapeutics analysis?
Beam is a clinical-stage test of whether base editing can become a repeatable product platform. Risto-cel is the nearest commercial opportunity; BEAM-302 is the strongest in vivo validation; and BEAM-301 plus BEAM-304 test scalability across liver diseases and mutations. Substantial liquidity, partner validation, and internal capabilities support the strategy, while clinical, regulatory, manufacturing, reimbursement, intellectual-property, and financing risks remain decisive.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.